Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EARLY-PA: Eplerenone for Prevention of Hypertension in Subclinical Primary Aldosteronism
NCT07727252Phase 3Not yet recruiting
- Sponsor
- Xinjiang Medical University
- Start
- Aug 2026
- Primary completion
- Aug 2029
01
Overview
A Phase 3 trial of eplerenone in primary aldosteronism (PA), sponsored by Xinjiang Medical University. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
eplerenone
03
Conditions
primary aldosteronism (PA)
Beyond the preview
Go deeper on NCT07727252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07727252.